Hostname: page-component-7bb8b95d7b-fmk2r Total loading time: 0 Render date: 2024-10-02T18:23:01.178Z Has data issue: false hasContentIssue false
  • English
  • Français

Supplement 4: Canadian Guidelines on Parkinson's Disease

Published online by Cambridge University Press:  02 December 2014

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Other
Information
Canadian Journal of Neurological Sciences , Volume 39 , Issue S4 , July 2012 , pp. S1 - S30
Copyright
Copyright © The Canadian Journal of Neurological 2012

References

1Gibb, WR, Lees, AJ.The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745–52.CrossRefGoogle Scholar
2Schrag, A, Ben-Shlomo, Y, Quinn, N.How valid is the clinical diagnosis of Parkinson’s disease in the community? J Neurol Neurosurg Psychiatry. 2002;73(5):529–34.CrossRefGoogle ScholarPubMed
3Olanow, CW, Rascol, O, Hauser, R, et al.A double-blind, delayedstart trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009;361 (13):1268–78.CrossRefGoogle ScholarPubMed
4Schapira, AH, Obeso, J.Timing of treatment initiation in Parkinson’s disease: a need for reappraisal? Ann Neurol. 2006;59(3):559–62.CrossRefGoogle ScholarPubMed
5Stocchi, F, Rascol, O, Kieburtz, K, et al.Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18–27.CrossRefGoogle ScholarPubMed
6Weintraub, D, Koester, J, Potenza, MN, et al.Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–95.CrossRefGoogle ScholarPubMed
7Hassan, A, Bower, JH, Kumar, N, et al.Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat Disord. 2011;17(4):260–4.CrossRefGoogle ScholarPubMed
8Moro, E, Lozano, AM, Pollak, P, et al.Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson’s disease. Mov Disord. 2010;25(5):578–86.CrossRefGoogle ScholarPubMed
9Hamani, C, Lozano, AM.Hardware-related complications of deep brain stimulation: a review of the published literature. Stereotact Funct Neurosurg. 2006;84(5-6):248–51.CrossRefGoogle ScholarPubMed
10Hariz, MI, Rehncrona, S, Quinn, NP, Speelman, JD, Wensing, C.Multicenter study on deep brain stimulation in Parkinson’s disease: an independent assessment of reported adverse events at 4 years. Mov Disord. 2008;23(3):416–21.CrossRefGoogle ScholarPubMed
11Deuschl, G, Schade-Brittinger, C, Krack, P, et al.A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2006;355(9):896–908.CrossRefGoogle ScholarPubMed
12Weaver, FM, Follett, K, Stern, M, et al.Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63–73.CrossRefGoogle ScholarPubMed
13Pahwa, R, Lyons, KE, Wilkinson, SB, et al.Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg. 2006;104(4): 506–12.CrossRefGoogle ScholarPubMed
14Hariz, MI, Krack, P, Alesch, F, et al.Multicentre European study of thalamic stimulation for parkinsonian tremor: a 6 year follow-up. J Neurol Neurosurg Psychiatry. 2008;79(6):694–9.CrossRefGoogle Scholar
15Derost, PP, Ouchchane, L, Morand, D, et al.Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology. 2007;68(17):1345–55.CrossRefGoogle Scholar
16Schupbach, WM, Maltete, D, Houeto, JL, et al.Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology. 2007;68(4):267–71.CrossRefGoogle ScholarPubMed
17Ravina, B, Camicioli, R, Como, PG, et al.The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69(4):342–7.CrossRefGoogle ScholarPubMed
18Menza, M, Dobkin, RD, Marin, H, et al.A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72(10):886–92.CrossRefGoogle ScholarPubMed
19Antonini, A, Tesei, S, Zecchinelli, A, et al.Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson’s disease and depression: effect on quality of life. Mov Disord. 2006;21(8):1119–22.CrossRefGoogle ScholarPubMed
20Devos, D, Dujardin, K, Poirot, I, et al.Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23(6):850–7.CrossRefGoogle ScholarPubMed
21Weintraub, D, Mavandadi, S, Mamikonyan, E, et al.Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75(5):448–55.CrossRefGoogle ScholarPubMed
22Barone, P, Poewe, W, Albrecht, S, et al.Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573–80.CrossRefGoogle ScholarPubMed
23Friedman, JH.Parkinson’s disease psychosis 2010: a review article. Parkinsonism Relat Disord. 2010;16(9):553–60.CrossRefGoogle ScholarPubMed
24Rabey, JM, Prokhorov, T, Miniovitz, A, Dobronevsky, E, Klein, C.Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord. 2007;22(3):313–8.CrossRefGoogle ScholarPubMed
25Shotbolt, P, Samuel, M, Fox, C, David, AS.A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease. Neuropsychiatr Dis Treat. 2009;5:327–32.CrossRefGoogle ScholarPubMed
26Merims, D, Balas, M, Peretz, C, Shabtai, H, Giladi, N.Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin Neuropharmacol. 2006;29(6): 331–7.CrossRefGoogle ScholarPubMed
27Hely, MA, Reid, WG, Adena, MA, Halliday, GM, Morris, JG.The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–44.CrossRefGoogle Scholar
28Aarsland, D, Ballard, C, Walker, Z, et al.Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613–8.CrossRefGoogle ScholarPubMed
29Grace, J, Amick, MM, Friedman, JH.A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J Neurol Neurosurg Psychiatry. 2009;80(1):18–23.CrossRefGoogle ScholarPubMed
30Emre, M, Tsolaki, M, Bonuccelli, U, et al.Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–77.CrossRefGoogle ScholarPubMed
31Dauvilliers, Y.Insomnia in patients with neurodegenerative conditions. Sleep Med. 2007;8 Suppl 4:S27–34.CrossRefGoogle ScholarPubMed
32Montgomery, P, Dennis, J.A systematic review of nonpharmacological therapies for sleep problems in later life. Sleep Med Rev. 2004;8(1):47–62.CrossRefGoogle ScholarPubMed
33Dowling, GA, Mastick, J, Colling, E, Carter, JH, Singer, CM, Aminoff, MJ.Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med. 2005;6(5):459–66.CrossRefGoogle ScholarPubMed
34Medeiros, CA, Carvalhedo de Bruin, PF, Lopes, LA, Magalhaes, MC, de Lourdes Seabra, M, de Bruin, VM.Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease. A randomized, double blind, placebo-controlled study. J Neurol. 2007;254(4):459–64.CrossRefGoogle ScholarPubMed
35Leeman, AL, O’Neill, CJ, Nicholson, PW, et al.Parkinson’s disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol. 1987;24(5):637–43.CrossRefGoogle ScholarPubMed
36Stocchi, F, Barbato, L, Nordera, G, Berardelli, A, Ruggieri, S.Sleep disorders in Parkinson’s disease. J Neurol. 1998;245 Suppl 1:S15–8.CrossRefGoogle ScholarPubMed
37Menza, M, Dobkin, RD, Marin, H, et al.Treatment of insomnia in Parkinson’s disease: a controlled trial of eszopiclone and placebo. Mov Disord. 2010;25(11):1708–14.CrossRefGoogle ScholarPubMed
38Zesiewicz, TA, Sullivan, KL, Arnulf, I, et al.Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74(11):924–31.CrossRefGoogle Scholar
39Gagnon, JF, Postuma, RB, Mazza, S, Doyon, J, Montplaisir, J.Rapideye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol. 2006;5(5):424–32.CrossRefGoogle ScholarPubMed
40Gagnon, JF, Postuma, RB, Montplaisir, J.Update on the pharmacology of REM sleep behavior disorder. Neurology. 2006;67(5):742–7.CrossRefGoogle ScholarPubMed
41Aurora, RN, Zak, RS, Maganti, RK, et al.Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85–95.Google ScholarPubMed
42Ferini-Strambi, L, Manconi, M.Treatment of restless legs syndrome. Parkinsonism Relat Disord. 2009;15 Suppl 4:S65–70.CrossRefGoogle ScholarPubMed
43Arnulf, I.Excessive daytime sleepiness in parkinsonism. Sleep Med Rev. 2005;9(3):185–200.CrossRefGoogle ScholarPubMed
44Cochen De Cock, V, Abouda, M, Leu, S, et al.Is obstructive sleep apnea a problem in Parkinson’s disease? Sleep Med. 2010;11(3):247–52.CrossRefGoogle ScholarPubMed
45Adler, CH, Caviness, JN, Hentz, JG, Lind, M, Tiede, J.Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord. 2003;18(3):287–93.CrossRefGoogle ScholarPubMed
46Ondo, WG, Fayle, R, Atassi, F, Jankovic, J.Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76(12):1636–9.CrossRefGoogle ScholarPubMed
47Hogl, B, Saletu, M, Brandauer, E, et al.Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25(8):905–9.CrossRefGoogle ScholarPubMed
48Magerkurth, C, Schnitzer, R, Braune, S.Symptoms of autonomic failure in Parkinson’s disease: prevalence and impact on daily life. Clin Auton Res. 2005;15(2):76–82.CrossRefGoogle ScholarPubMed
49Chaudhuri, KR, Healy, DG, Schapira, AH.Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–45.CrossRefGoogle ScholarPubMed
50Bachmann, CG, Trenkwalder, C.Body weight in patients with Parkinson’s disease. Mov Disord. 2006;21(11):1824–30.CrossRefGoogle ScholarPubMed
51Barichella, M, Cereda, E, Pezzoli, G.Major nutritional issues in the management of Parkinson’s disease. Mov Disord. 2009;24(13):1881–92.CrossRefGoogle ScholarPubMed
52Naumann, M, So, Y, Argoff, CE, et al.Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1707–14.CrossRefGoogle Scholar
53Hyson, HC, Johnson, AM, Jog, MS.Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord. 2002;17 (6):1318–20.CrossRefGoogle ScholarPubMed
54Molloy, L.Treatment of sialorrhoea in patients with Parkinson’s disease: best current evidence. Curr Opin Neurol. 2007;20(4):493–8.CrossRefGoogle ScholarPubMed
55Thomsen, TR, Galpern, WR, Asante, A, Arenovich, T, Fox, SH.Ipratropium bromide spray as treatment for sialorrhea in Parkinson’s disease. Mov Disord. 2007;22(15):2268–73.CrossRefGoogle ScholarPubMed
56Simuni, T, Sethi, K.Nonmotor manifestations of Parkinson’s disease. Ann Neurol. 2008;64 Suppl 2:S65–80.CrossRefGoogle ScholarPubMed
57Chancellor, MB, Anderson, RU, Boone, TB.Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil. 2006;85(6):536–45.CrossRefGoogle ScholarPubMed
58Mostile, G, Jankovic, J.Treatment of dysautonomia associated with Parkinson’s disease. Parkinsonism Relat Disord. 2009;15 Suppl 3:S224–32.CrossRefGoogle ScholarPubMed
59Santos, JC, Telo, ER.Solifenacin: scientific evidence in the treatment of overactive bladder. Arch Esp Urol. 2010;63(3):197–213.Google ScholarPubMed
60Abbott, RD, Ross, GW, Petrovitch, H, et al.Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord. 2007;22(11):1581–6.CrossRefGoogle ScholarPubMed
61Goldstein, DS.Orthostatic hypotension as an early finding in Parkinson’s disease. Clin Auton Res. 2006;16(1):46–54.CrossRefGoogle ScholarPubMed
62Schoffer, KL, Henderson, RD, O’Maley, K, O’sullivan, JD.Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson’s disease. Mov Disord. 2007;22(11):1543–9.CrossRefGoogle ScholarPubMed